Natera, a global provider of cell-free DNA (cfDNA) testing, has acquired from Invitae, a medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business.
Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera.
“We are committed to providing excellent service, and we look forward to the opportunity to support additional patients and providers,” says Steve Chapman, CEO of Natera.
Natera has made an upfront payment of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits.
Natera says it is dedicated to oncology, women’s health, and organ health. The company aims to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Meanwhile, Invitae offers advanced genetic testing that can be easily integrated into medical practices, the company says.
Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California.
Further reading: Natera’s Lung Transplant Assessment Test Gets Medicare Coverage
